These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histological pattern.
    Author: Kumagai I, Masuda T, Sato S, Ishikawa K.
    Journal: Hepatol Res; 2001 Jul; 20(3):312-319. PubMed ID: 11404191.
    Abstract:
    We evaluated the immunoreactivity to monoclonal antibody for hepatocyte (Hep Par 1) and determined the cellular distribution of the antigen in hepatocellular carcinoma (HCC), based on the histopathological grade and histological pattern. The pathological material included 100 areas selected at random in 61 tissue sections from 12 autopsy livers with HCC. Immunoreactivity was classified into four categories; strongly positive (>90% of the area showed positive staining), moderately positive (5-90% of the area), weakly positive (<5% of the area), and negative (completely negative). All 19 (100%) well-differentiated, trabecular type HCC areas were strongly positive for Hep Par 1. Among 11 well-differentiated, pseudoglandular type HCC areas, 2 (18%) were strongly positive, 5 (46%) were moderately positive, 2 (18%) were weakly positive, and 2 (18%) were negative. Among 36 moderately differentiated, trabecular type HCC areas, 6 (17%) were strongly positive, 17 (47%) were moderately positive, 9 (25%) were weakly positive, and 4 (11%) were negative. None of the four moderately differentiated, pseudoglandular type HCC areas were strongly positive, 3 (75%) were moderately positive, 0 was weakly positive, and 1 (25%) was negative. Among 25 poorly differentiated, compact or trabecular type HCC areas, 15 (60%) were weakly positive and 10 (40%) were negative. All 5 (100%) undifferentiated HCC areas were negative for Hep Par 1. Our results indicate that immunoreactivity to Hep Par 1 in HCC decreases with reduced differentiation of the tumor, suggesting that Hep Par 1 monoclonal antibody is useful as a marker for the diagnosis and differentiation of HCCs.
    [Abstract] [Full Text] [Related] [New Search]